特发性非肝硬化性门静脉高压患者因静脉曲张出血行TIPSS与肝硬化患者的比较
本研究比较了活检证实的特发性非肝硬化性门静脉高压(INCPH)患者与匹配的肝硬化患者因静脉曲张出血接受经颈静脉肝内门体分流术(TIPSS)后的结局。结果显示INCPH患者5年死亡率(11% vs 36%)、显性肝性脑病(16% vs 33%)和肝功能衰竭均显著低于肝硬化组,而再出血和分流功能障碍率相似。
要点
- INCPH患者TIPSS后5年死亡率11%,肝硬化组36%(校正HR 0.37,95%CI 0.15-0.87,P=0.022)。
- INCPH组5年显性肝性脑病16%,肝硬化组33%(校正HR 0.35,95%CI 0.16-0.75,P=0.007)。
- 两组5年再出血率(33% vs 32%)和分流功能障碍率(35% vs 36%)无显著差异。
核心结论
- INCPH患者因静脉曲张出血接受TIPSS后,门静脉高压进展(再出血和分流功能障碍)与肝功能相当的肝硬化患者相似,但肝病并发症(显性肝性脑病和肝功能衰竭)更少,死亡率更低。
研究设计与样本
- 2001年3月至2015年9月,纳入76例活检证实的INCPH因静脉曲张出血接受TIPSS的连续患者,以76例年龄、性别、Child-Pugh分级、支架类型和TIPSS创建年份匹配的肝硬化门静脉高压患者为对照。
主要发现
- INCPH组与肝硬化组5年死亡率分别为11%和36%(校正HR 0.37,95%CI 0.15-0.87,P=0.022)。
- INCPH组与肝硬化组5年显性肝性脑病发生率分别为16%和33%(校正HR 0.35,95%CI 0.16-0.75,P=0.007)。
- INCPH组与肝硬化组5年再出血率分别为33%和32%(校正HR 0.72,95%CI 0.36-1.44,P=0.358),分流功能障碍率分别为35%和36%(校正HR 0.84,95%CI 0.41-1.72,P=0.627)。
- 上述结果在不同相关亚组中一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with idiopathic non-cirrhotic portal hypertension (INCPH), the usual recommended strategy for management of variceal bleeding is the same as that in cirrhosis. However, this policy has been challenged by the different natural history between INCPH and cirrhosis. AIM: To compare outcomes after transjugular intrahepatic portosystemic shunt (TIPSS) between INCPH and cirrhotic patients admitted for variceal bleeding. METHODS: Between March 2001 and September 2015, 76 consecutive patients with biopsy-proven INCPH undergoing TIPSS for variceal bleeding in a tertiary-care centre were included. 76 patients with cirrhotic portal hypertension receiving TIPSS for variceal bleeding, and matched for age, sex, Child-Pugh class, stent type and index year of TIPSS creation served as controls. RESULTS: Patients with INCPH, compared to those with cirrhosis, had significantly lower mortality (11% vs 36% at 5 years, adjusted HR, 0.37; 95% CI 0.15-0.87, P = 0.022), overt hepatic encephalopathy (16% vs 33% at 5 years, adjusted HR, 0.35; 95% CI 0.16-0.75, P = 0.007) and hepatic impairment, despite similar rates of further bleeding (33% vs 32% at 5 years, adjusted HR, 0.72; 95% CI 0.36-1.44, P = 0.358), and shunt dysfunction (35% vs 36% at 5 years, adjusted HR, 0.84; 95% CI 0.41-1.72, P = 0.627). These findings were consistent across different relevant subgroups. CONCLUSIONS: Patients with INCPH treated with TIPSS for variceal bleeding had similar progression of portal hypertension (further bleeding and shunt dysfunction) but fewer complications of liver disease (overt hepatic encephalopathy and hepatic insufficiency) and lower mortality rate compared with cirrhotic patients with comparable liver function.
引用
- Lv Y, Li K, He C, et al. TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosis. Aliment Pharmacol Ther. 2019. PMID: 30820990. doi:10.1111/apt.15186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。